Blueprint Medicines to Present at 32nd Annual J.P. Morgan Healthcare Conference
Company to provide overview of product engine and resulting pipeline of highly selective, genomically defined product candidates
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Blueprint Medicines today announced that Alexis Borisy, president and interim chief executive officer, will present a company overview at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 15, 2014 at 10:00 am PT (1:00 pm ET). The overview will include the Company’s progress in developing its product engine and resulting pipeline of selective, genomically defined product candidates, as well as Blueprint’s 2014 goals and strategy for long-term growth.
About Blueprint Medicines
Blueprint Medicines is a patient-driven oncology company developing highly selective kinase inhibitors for genomically-defined cancer subsets. Led by a management team and advisors with world-renowned expertise in cancer genomics, drug discovery and clinical oncology, Blueprint has developed a platform that combines genomics with a novel library of kinase inhibitors, enabling Blueprint to rapidly develop potent highly selective compounds against clear genomic driver targets. Founded in 2011, Blueprint is privately held and initially backed by Third Rock Ventures and Fidelity BioSciences. For more information, please visit BlueprintMedicines.com.